Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679374 · ClinicalTrials.gov registry record · Phase 2
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
A Phase 2 study of Parkinson Disease, sponsored by Vikas Kotagal.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT06679374: Recruiting Phase 2 study of Parkinson Disease, sponsored by Vikas Kotagal.
NCT06679374 is a Phase 2 study of Parkinson Disease that is actively recruiting participants, run by Vikas Kotagal. The registered enrollment target is 102 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06679374, a Phase 2 study of Parkinson Disease, is actively recruiting participants, sponsored by Vikas Kotagal.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the study medication participants will have visits (over the phone and in person), various tests and imaging, questionnaires, and laboratory collections.
Primary Outcome
Normal pace-dual task cost is defined as the within-subject difference between normal pace walking speed without dual tasking to normal pace walking speed with dual tasking divided by normal pace walking speed without dual tasking, multiplied by 100.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT06679374 shows while recruiting
NCT06679374 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06679374 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06679374 about?
NCT06679374 is a clinical study titled "Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease". This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the s...
What is the current status of trial NCT06679374?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2025-04-09. Estimated completion is 2027-01.
What conditions does trial NCT06679374 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06679374?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT06679374?
This trial is sponsored by Vikas Kotagal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679374 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06679374's enrollment target sits among peer trials
102 85th of 297 higher than 213 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI